Structural Basis for Nucleotide
Binding and Reaction
Catalysis in Mevalonate Diphosphate Decarboxylase
- Publication date
- Publisher
Abstract
Mevalonate diphosphate decarboxylase (MDD) catalyzes
the final
step of the mevalonate pathway, the Mg<sup>2+</sup>-ATP dependent
decarboxylation of mevalonate 5-diphosphate (MVAPP), producing isopentenyl
diphosphate (IPP). Synthesis of IPP, an isoprenoid precursor molecule
that is a critical intermediate in peptidoglycan and polyisoprenoid
biosynthesis, is essential in Gram-positive bacteria (e.g., <i>Staphylococcus</i>, <i>Streptococcus</i>, and <i>Enterococcus</i> spp.), and thus the enzymes of the mevalonate
pathway are ideal antimicrobial targets. MDD belongs to the GHMP superfamily
of metabolite kinases that have been extensively studied for the past
50 years, yet the crystallization of GHMP kinase ternary complexes
has proven to be difficult. To further our understanding of the catalytic
mechanism of GHMP kinases with the purpose of developing broad spectrum
antimicrobial agents that target the substrate and nucleotide binding
sites, we report the crystal structures of wild-type and mutant (S192A
and D283A) ternary complexes of <i>Staphylococcus epidermidis</i> MDD. Comparison of apo, MVAPP-bound, and ternary complex wild-type
MDD provides structural information about the mode of substrate binding
and the catalytic mechanism. Structural characterization of ternary
complexes of catalytically deficient MDD S192A and D283A (<i>k</i><sub>cat</sub> decreased 10<sup>3</sup>- and 10<sup>5</sup>-fold, respectively) provides insight into MDD function. The carboxylate
side chain of invariant Asp<sup>283</sup> functions as a catalytic
base and is essential for the proper orientation of the MVAPP C3-hydroxyl
group within the active site funnel. Several MDD amino acids within
the conserved phosphate binding loop (“P-loop”) provide
key interactions, stabilizing the nucleotide triphosphoryl moiety.
The crystal structures presented here provide a useful foundation
for structure-based drug design